Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas.

Immunocytochemistry (ICC) has been used routinely to stain for p53 overexpression in a range of human tumours. The underlying assumption has been that positive staining indicates a mutation in the p53 coding sequence. Recently, however, discordancy has been observed and the accuracy of ICC as a marker of p53 gene mutation has been questioned. In this study of 109 colorectal adenocarcinomas, we compared ICC staining with p53 gene mutations detected by single-strand conformation polymorphism (SSCP) analysis. Concordancy between the two techniques was found in 69% of tumours. ICC-positive/SSCP-negative cases accounted for 20% of tumours and ICC-negative/SSCP-positive cases for the remaining 11%. These results caution against the assumption that p53 protein overexpression is always associated with a gene mutation. Epigenetic phenomena may account for a significant proportion of ICC-positive tumours.

[1]  Y. Nakamura,et al.  Allelotype of colorectal carcinomas. , 1989, Science.

[2]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Minna,et al.  Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. , 1992, Oncogene.

[4]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[5]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[6]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[7]  P. Humphrey,et al.  Overexpression and mutation of p53 in endometrial carcinoma. , 1992, Cancer research.

[8]  B. Vogelstein,et al.  An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms , 1994, The Journal of pathology.

[9]  Medicine,et al.  Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.

[10]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[11]  J. Bartek,et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.

[12]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[13]  A. Gown,et al.  Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. , 1992, The American journal of pathology.

[14]  T. Visakorpi,et al.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. , 1992, Journal of the National Cancer Institute.

[15]  G. Taylor,et al.  Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. , 1993, Gastroenterology.

[16]  B. Iacopetta,et al.  The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short‐term prognostic indicators of survival , 1994, International journal of cancer.

[17]  M. Seki,et al.  Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. , 1992, Cancer research.

[18]  H. Zhang,et al.  Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma , 1992, The Lancet.

[19]  U. Veronesi,et al.  p53 as an independent prognostic marker in lymph node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.

[20]  C. Purdie,et al.  p53 expression in colorectal tumors. , 1991, The American journal of pathology.

[21]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[22]  D. Wynford‐Thomas.  P53 in tumour pathology: Can we trust immunocytochemistry? , 1992, The Journal of pathology.

[23]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[24]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[25]  A. Levine,et al.  Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells , 1982, Cell.

[26]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[27]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[28]  S. Benchimol,et al.  The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. , 1993, The EMBO journal.

[29]  G. Casey,et al.  Frequent p53 mutations in head and neck cancer. , 1992, Cancer research.

[30]  P. Hall,et al.  Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. , 1991, British Journal of Cancer.

[31]  D. Schaid,et al.  Expression of p53 and 17p allelic loss in colorectal carcinoma. , 1992, Cancer research.

[32]  J. Marks,et al.  Genetic basis for p53 overexpression in human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Sasano,et al.  Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. , 1993, Anticancer research.

[34]  I. Miyazaki,et al.  Expression of p53 protein in colorectal cancer and its relationship to short‐term prognosis , 1992, Cancer.

[35]  G. Thomas,et al.  Increased p53 protein content of colorectal tumours correlates with poor survival. , 1992, British Journal of Cancer.

[36]  B. Dutrillaux,et al.  Consistent deficiencies of chromosome 18 and of the short arm of chromosome 17 in eleven cases of human large bowel cancer: a possible recessive determinism. , 1985, Annales de genetique.

[37]  P. Humphrey,et al.  Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. , 1993, Obstetrics and gynecology.

[38]  G. Bevilacqua,et al.  Immunocytochemical p53 detection by microwave oven heating of routinely formalin‐fixed paraffin sections , 1993, The Journal of pathology.

[39]  R. Maestro,et al.  High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. , 1992, Oncogene.

[40]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[41]  R. Lothe,et al.  Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors. , 1992, Journal of the National Cancer Institute.

[42]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[43]  S. Friend,et al.  Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Eyfjörd,et al.  Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. , 1993, Cancer research.